959 related articles for article (PubMed ID: 28826184)
41. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
[TBL] [Abstract][Full Text] [Related]
43. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.
Eckerström C; Olsson E; Bjerke M; Malmgren H; Edman A; Wallin A; Nordlund A
J Alzheimers Dis; 2013; 36(3):421-31. PubMed ID: 23635408
[TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
45. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
[TBL] [Abstract][Full Text] [Related]
46. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
[TBL] [Abstract][Full Text] [Related]
47. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
48. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
[TBL] [Abstract][Full Text] [Related]
49. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
[TBL] [Abstract][Full Text] [Related]
50. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
51. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease.
Nasiri E; Sankowski R; Dietrich H; Oikonomidi A; Huerta PT; Popp J; Al-Abed Y; Bacher M
Mol Med; 2020 Apr; 26(1):34. PubMed ID: 32303185
[TBL] [Abstract][Full Text] [Related]
52. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
[TBL] [Abstract][Full Text] [Related]
53. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
[TBL] [Abstract][Full Text] [Related]
54. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
Le Bastard N; Aerts L; Sleegers K; Martin JJ; Van Broeckhoven C; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2013; 33(3):807-22. PubMed ID: 23034521
[TBL] [Abstract][Full Text] [Related]
56. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
[TBL] [Abstract][Full Text] [Related]
57. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
58. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
59. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
60. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
